"Vrozen\u00E9 a z\u00EDskan\u00E9 trombofiln\u00ED stavy p\u0159edstavuj\u00ED riziko tromboembolick\u00E9 nemoci a specifick\u00FDch poruch gravidity. L\u00E9\u010Dba heparinem umo\u017E\u0148uje tato rizika v\u00FDrazn\u011B omezit. Jsou definov\u00E1na krit\u00E9ria indikuj\u00EDc\u00ED laboratorn\u00ED vy\u0161et\u0159en\u00ED trombofiln\u00EDch stav\u016F. U\u017Eit\u00ED profylaktick\u00FDch nebo terapeutick\u00FDch d\u00E1vek heparinu vypl\u00FDvaj\u00ED z konkr\u00E9tn\u00ED klinick\u00E9 situace a m\u00EDry individu\u00E1ln\u00EDho rizika. Komplexn\u00ED p\u0159\u00EDstup zahrnuje i pr\u016Fb\u011B\u017En\u00E9 sledov\u00E1n\u00ED stavu plodu pomoc\u00ED ultrasonografie a kardiotokografie. Indikovan\u00E1 antikoagula\u010Dn\u00ED l\u00E9\u010Dba mus\u00ED b\u00FDt aplikov\u00E1na i v pr\u016Fb\u011Bhu 6-8 t\u00FDdn\u016F po porodu. Ze zji\u0161t\u011Bn\u00E9ho trombofiln\u00EDho stavu by m\u011Bla b\u00FDt vyvozena opat\u0159en\u00ED omezuj\u00EDc\u00ED dal\u0161\u00ED potenci\u00E1ln\u00ED rizika."@cs . . . . "Vrozen\u00E9 a z\u00EDskan\u00E9 trombofiln\u00ED stavy p\u0159edstavuj\u00ED riziko tromboembolick\u00E9 nemoci a specifick\u00FDch poruch gravidity. L\u00E9\u010Dba heparinem umo\u017E\u0148uje tato rizika v\u00FDrazn\u011B omezit. Jsou definov\u00E1na krit\u00E9ria indikuj\u00EDc\u00ED laboratorn\u00ED vy\u0161et\u0159en\u00ED trombofiln\u00EDch stav\u016F. U\u017Eit\u00ED profylaktick\u00FDch nebo terapeutick\u00FDch d\u00E1vek heparinu vypl\u00FDvaj\u00ED z konkr\u00E9tn\u00ED klinick\u00E9 situace a m\u00EDry individu\u00E1ln\u00EDho rizika. Komplexn\u00ED p\u0159\u00EDstup zahrnuje i pr\u016Fb\u011B\u017En\u00E9 sledov\u00E1n\u00ED stavu plodu pomoc\u00ED ultrasonografie a kardiotokografie. Indikovan\u00E1 antikoagula\u010Dn\u00ED l\u00E9\u010Dba mus\u00ED b\u00FDt aplikov\u00E1na i v pr\u016Fb\u011Bhu 6-8 t\u00FDdn\u016F po porodu. Ze zji\u0161t\u011Bn\u00E9ho trombofiln\u00EDho stavu by m\u011Bla b\u00FDt vyvozena opat\u0159en\u00ED omezuj\u00EDc\u00ED dal\u0161\u00ED potenci\u00E1ln\u00ED rizika." . "Congenital and acquired thrombophilic states pose a risk of thromboembolic disease and pregnancy-specific disorders. Treatment with heparin can significantly reduce these risks. Defined criteria indicate laboratory tests for thrombophilia. The use of prophylactic or therapeutic doses of heparin result from a particular clinical situation and the level of individual risk. A comprehensive approach includes ongoing monitoring of the fetus using ultrasonography and cardiotocography. Indicated anticoagulant treatment must be applied in the course of 6-8 weeks after birth. From the observed prothrombotic state should be inferred measures restricting other potential risks."@en . "9" . "[2D945C17023D]" . "V" . "Thrombophilia and pregrancy"@en . "Trombofilie a t\u011Bhotenstv\u00ED" . "Trombofilie a t\u011Bhotenstv\u00ED"@cs . "1"^^ . . "4"^^ . "RIV/00216208:11120/07:00003003!RIV12-MSM-11120___" . . . "Postgradu\u00E1ln\u00ED medic\u00EDna" . "Trombofilie a t\u011Bhotenstv\u00ED" . "11120" . "1" . . . "K\u0159epelka, Petr" . "Trombofilie a t\u011Bhotenstv\u00ED"@cs . "Thrombophilia; pregrancy"@en . "RIV/00216208:11120/07:00003003" . "CZ - \u010Cesk\u00E1 republika" . . . . "Thrombophilia and pregrancy"@en . "1"^^ . . "455880" . . "1212-4184" .